艾德生物
(300685)
| 流通市值：99.12亿 | | | 总市值：100.03亿 |
| 流通股本：3.95亿 | | | 总股本：3.99亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 736,841,008.77 | 804,534,209.54 | 706,466,702.8 | 552,789,166.67 |
| 应收票据及应收账款 | 584,567,059.45 | 571,451,622.92 | 518,021,953.62 | 535,459,605.95 |
| 其中：应收票据 | 10,723,097.87 | 10,943,854.28 | 13,663,073.55 | 13,012,888.32 |
| 应收账款 | 573,843,961.58 | 560,507,768.64 | 504,358,880.07 | 522,446,717.63 |
| 预付款项 | 12,502,342.1 | 10,495,771.7 | 9,612,404.5 | 10,932,496.65 |
| 其他应收款合计 | 2,516,015.9 | 2,273,057.28 | 2,297,419.57 | 2,524,239.77 |
| 存货 | 37,320,993.03 | 33,050,195.3 | 31,527,239.07 | 28,782,648.84 |
| 合同资产 | 2,888,146.64 | 2,612,563.78 | 1,391,399.66 | 1,553,326.45 |
| 一年内到期的非流动资产 | 11,062,145.3 | 10,930,954.32 | 10,801,808.16 | 10,672,662 |
| 其他流动资产 | 6,312,142.46 | 4,502,022.44 | 5,267,699.33 | 8,636,501.72 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,743,106,265.64 | 1,691,758,828.49 | 1,667,794,352.52 | 1,620,471,886.98 |
| 非流动资产: | | | | |
| 长期应收款 | 23,730,409.7 | 23,498,516.18 | 23,221,529.12 | 22,944,542.06 |
| 长期股权投资 | 20,574,590.68 | 22,367,555.96 | 30,798,576.69 | 32,004,360.44 |
| 固定资产 | 182,566,429.72 | 182,924,744 | 186,561,060.9 | 188,682,658.7 |
| 使用权资产 | 5,622,163.48 | 6,398,539.93 | 4,388,633.39 | 5,203,314.69 |
| 无形资产 | 45,347,653.38 | 47,113,553.98 | 47,096,284.47 | 48,548,154.11 |
| 长期待摊费用 | 4,429,784.24 | 5,019,306.26 | 5,687,452.02 | 6,337,041.71 |
| 递延所得税资产 | 8,417,345.15 | 6,784,678.48 | 6,280,820.35 | 5,249,217.66 |
| 其他非流动资产 | 1,800,378.6 | 2,342,303.6 | 2,529,391.51 | 5,440,376.67 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 292,488,754.95 | 296,449,198.39 | 306,563,748.45 | 314,409,666.04 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,035,595,020.59 | 1,988,208,026.88 | 1,974,358,100.97 | 1,934,881,553.02 |
| 流动负债: | | | | |
| 短期借款 | 5,004,794.52 | 5,004,794.52 | 5,004,794.52 | 5,004,794.52 |
| 应付票据及应付账款 | 21,170,445.3 | 17,655,989.63 | 16,485,037.59 | 17,896,879.85 |
| 应付账款 | 21,170,445.3 | 17,655,989.63 | 16,485,037.59 | 17,896,879.85 |
| 预收款项 | 191,322.67 | 14,120 | 649,745.5 | 649,745.5 |
| 合同负债 | 5,647,775.41 | 4,102,176.19 | 3,976,522.27 | 4,336,120.59 |
| 应付职工薪酬 | 53,884,728.9 | 41,769,892.66 | 29,834,817.14 | 42,163,694.3 |
| 应交税费 | 18,377,317.04 | 16,826,358.51 | 22,844,176.46 | 25,635,693.49 |
| 其他应付款合计 | 64,032,500.57 | 77,980,232.18 | 63,932,805.35 | 73,632,480.91 |
| 应付股利 | - | 11,839,718.16 | - | - |
| 一年内到期的非流动负债 | 47,944,176.61 | 48,569,636.21 | 4,568,842.66 | 5,110,279.11 |
| 其他流动负债 | 65,903.68 | 37,617 | 61,331.41 | 47,003.89 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 216,318,964.7 | 211,960,816.9 | 147,358,072.9 | 174,476,692.16 |
| 非流动负债: | | | | |
| 长期借款 | - | - | 43,780,000 | 44,400,000 |
| 租赁负债 | 2,737,297.34 | 3,746,705.25 | 1,957,637.03 | 2,166,991.07 |
| 递延收益 | 8,077,960.01 | 8,847,688.83 | 9,682,326.27 | 10,516,963.71 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 10,815,257.35 | 12,594,394.08 | 55,419,963.3 | 57,083,954.78 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 227,134,222.05 | 224,555,210.98 | 202,778,036.2 | 231,560,646.94 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 398,540,309 | 398,540,309 | 398,602,309 | 398,602,309 |
| 资本公积 | 240,852,345.62 | 234,475,473.56 | 226,719,939.92 | 218,296,666.28 |
| 减:库存股 | 136,777,148.97 | 91,179,033.86 | 55,436,250.11 | 51,664,415 |
| 其他综合收益 | 2,404,126.02 | 1,794,121.82 | 2,065,366.5 | 2,347,316.08 |
| 盈余公积 | 128,577,301.26 | 128,577,301.26 | 128,577,301.26 | 128,577,301.26 |
| 未分配利润 | 1,174,863,865.61 | 1,091,444,644.12 | 1,071,051,398.2 | 1,007,161,728.46 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,808,460,798.54 | 1,763,652,815.9 | 1,771,580,064.77 | 1,703,320,906.08 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,808,460,798.54 | 1,763,652,815.9 | 1,771,580,064.77 | 1,703,320,906.08 |
| 负债和股东权益合计 | 2,035,595,020.59 | 1,988,208,026.88 | 1,974,358,100.97 | 1,934,881,553.02 |
| 公告日期 | 2024-10-22 | 2024-07-30 | 2024-04-23 | 2024-04-16 |
| 审计意见(境内) | | | | 标准无保留意见 |